The Gilenya Pregnancy Registry

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects in the offspring of women exposed to fingolimod before (up to 8 weeks before last menstrual period (LMP)) and during pregnancy in routine clinical practice. The overall aim is to collect and evaluate data on maternal, fetal, and infant outcomes and compare it with reference populations.
Epistemonikos ID: 9d545f1d2e331090b3e435eba3e980b15e1356a3
First added on: May 06, 2024